Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective
Xiaoli Mu, Yan Li · 2024
Read Case report: Therapeutic response to lorlatinib in advanced large-cell neuroendocrine carcinoma of the lung and breast cancer: a heterochronous double malignancy perspective by Xiaoli Mu, Yan Li (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11669055.txt.
Description
Xiaoli Mu and Yan Li present a case report from 2024 on a woman with two separate cancers. Ten years after recovery from breast cancer, the 55-year-old patient developed a rare, fast-growing lung cancer called large-cell neuroendocrine carcinoma. By the time it was found, the cancer had spread to her brain.
Tests showed her lung tumour carried a gene fusion in the ALK gene, a change that is rare in this cancer type. She was treated first with lorlatinib, a drug that targets that change. After six weeks, her tumours had shrunk a great deal, rated as a partial response. Treatment continued for more than 25 months. The authors suggest such patients may gain real benefit from the targeted drug.
Catalog record
| CREATOR | Xiaoli Mu, Yan Li |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |